Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Synapse defective Rho GTPase homolog 2 (SYDE2) is an enzyme of the RhoGAP family found primarily in the cytosol and synaptic membrane, where it acts as a GTPase activator for Rho-type GTPases by converting them to an inactive GDP-bound state[3][5][8]. SYDE2 contains conserved C2 and RhoGAP domains, mediating its role as a regulator of actin cytoskeleton dynamics, neuronal differentiation, and signaling during embryonic brain development[1][6]. Predicted protein-protein interaction sites and phosphorylation motifs are conserved, supporting a dynamic regulatory role in synaptic scaffolding and neuronal signaling complexes[1]. Disease-associated mutations (e.g., truncations) in SYDE2 can affect brain development or neurodevelopmental outcomes[1][3]. No approved drugs specifically interact with SYDE2, and the lack of crystal structure information currently limits structure-based drug discovery opportunities[1][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Synapse defective Rho GTPase homolog 2 (SYDE2).